Ornella Cantale

Orbassano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

Journal: The oncologist

Published: February 11, 2026

From Simple Scores to Intelligent Systems: Encouraging the Development, Validation and Adoption of Robust Prognostic Tools in Small Cell Lung Cancer.

From Simple Scores to Intelligent Systems: Encouraging the Development, Validation and Adoption of Robust Prognostic Tools in Small Cell Lung Cancer.

Journal: Technology in cancer research & treatment

Published: January 23, 2026

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 22, 2025

Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.

Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 08, 2025

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 25, 2025

Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review.

Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review.

Journal: Critical reviews in oncology/hematology

Published: May 17, 2024

A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study.

A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study.

Journal: ESMO open

Published: May 03, 2024

First-line immunotherapy in non-small cell lung cancer: how to select and where to go.

First-line immunotherapy in non-small cell lung cancer: how to select and where to go.

Journal: Expert review of respiratory medicine

Published: January 31, 2024

Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors.

Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors.

Journal: Thoracic cancer

Published: May 16, 2023

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.

Journal: Frontiers in endocrinology

Published: October 09, 2022

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.

Journal: International immunopharmacology

Published: May 25, 2022

International Survey on Frailty Assessment in Patients with Cancer.

International Survey on Frailty Assessment in Patients with Cancer.

Journal: The oncologist

Published: March 31, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026